Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
Viveksandeep T ChandrasekarBhanu Prasad VenkatesuluHarsh K PatelMarco SpadacciniJacob ManteuffelMayur RameshPublished in: Journal of medical virology (2020)
Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options.
Keyphrases
- sars cov
- randomized controlled trial
- end stage renal disease
- mechanical ventilation
- ejection fraction
- respiratory syndrome coronavirus
- chronic kidney disease
- peritoneal dialysis
- newly diagnosed
- prognostic factors
- clinical trial
- acute respiratory distress syndrome
- type diabetes
- skeletal muscle
- weight loss
- machine learning
- coronavirus disease
- case control
- phase iii
- deep learning
- respiratory tract
- drug induced
- double blind